Hereditary Spastic Paraplegia Comprehensive Panel
Use
This test is intended for individuals who have clinically or genetically driven suspicion of Hereditary Spastic Paraplegia (HSP). It is useful for patients with unexplained inherited etiology of HSP, early symptom onset, or an unspecified pattern of inheritance evident in the family history. Determining the genetic cause can aid in prognosis, management decisions, and family planning.
Special Instructions
Results from this comprehensive genetic test can provide insights into familial risk and inform potential medical interventions. Correct selection of the testing platform (Exome vs. Genome) should be based on available clinical information and desired coverage. Prioritize sample preparation and decide on additional analyses such as CNV testing where applicable.
Limitations
Test accuracy may be influenced by sample quality and the biological complexity of the condition. It may not detect all genetic anomalies associated with Hereditary Spastic Paraplegia. Comprehensive coverage is limited to the genes included within this panel and may miss mutations outside this selection or in repeat expansion areas. Variants of uncertain significance (VUS) may be identified, which require further research and correlation with clinical data.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided